Table 1.
No. | Rt | [M-H]− | MS/MS | Proposed structure |
---|---|---|---|---|
1 | 1.93 | 169 | 125 | Gallic acid* |
2 | 2.06 | 331 | 169 | Galloyl glucose |
3 | 2.10 | 331 | 169 | Galloyl glucose |
4 | 2.4 | 353 | 191, 179 | 5-O-Caffeoylquinic acid |
5 | 3.86 | 353 | 191, 179 | 3-O-Caffeoylquinic acid |
6 | 4.21 | 353 | 191, 179 | 4-O-Caffeoylquinic acid |
7 | 4.32 | 483 | 331, 169 | 2, 6 di-O-(α/β)-4C1- galloyl glucose* |
8 | 4.57 | 337 | 191, 163 | p-Coumaroylquinic acid |
9 | 4.75 | 483 | 331, 169 | 2,3 di-O-(α/β)-4C1- galloyl glucose* |
10 | 5.06 | 757 | 301, 613, 633 | Galloyl decarboxy valoneoyl glucoside |
11 | 9.94 | 183 | 183, 169 | Methyl gallate |
12 | 11.07 | 563 | 417, 285 | Kaempferol pentosyl rhamnoside |
13 | 15.87 | 385 | 223, 178 | Sinapic acid hexoside |
14 | 16.44 | 399 | 273, 179 | Monolactonoside didecarboxylated valoneoic acid |
15 | 17.97 | 275 | 275, 257, 229 | 3,4,8,9,10-pentahydroxy-6-oxobenzo[c]chromene |
16 | 17.24 | 595 | 463 | Myricetin-3-O-xylopyranosyl(1 → 2)-α-1C4-rhamnopyranoside* |
17 | 21.89 | 479 | 317 | Myricetin hexoside I |
18 | 22.84 | 367 | 191, 179 | Feruloylquinic acid |
19 | 23.03 | 479 | 317 | Myricetin hexoside II |
20 | 23.56 | 449 | 317 | Myricetin pentoside I |
21 | 24.54 | 449 | 317 | Myricetin pentoside II |
22 | 24.81 | 497 | 169, 183, 313, 341 | Gallic acid methyl ester (-O-galloyl) hexoside |
23 | 26.42 | 463 | 317 | Myricetin 3-O-α-1C4-rhamnopyranoside* |
24 | 27.71 | 463 | 317 | Myricetin rhamnoside I |
25 | 28.8 | 463 | 317 | Myricetin rhamnoside II |
26 | 31.80 | 491 | 359 | Tri-O-methyl myricetin pentoside |
27 | 32.78 | 447 | 301 | Quercetin deoxyhexoside |
28 | 38.33 | 431 | 285 | Kaempferol deoxyhexoside |
29 | 40.33 | 615 | 179, 301, 463 | Myricetin galloyl-rhamnoside I |
30 | 43.13 | 615 | 179, 301, 463 | Myricetin galloyl-rhamnoside II |
31 | 49.2 | 593 | 447, 285 | Kaempferol coumaroyl-hexoside |
32 | 51.98 | 657 | 495, 329 | Caffeoyl digalloyl quinic acid |
*Compounds isolated and identified during this study.